430 results on '"Müller, Cristina"'
Search Results
2. Opportunities and potential challenges of using terbium-161 for targeted radionuclide therapy in clinics
3. A tool for nuclear imaging of the SARS-CoV-2 entry receptor: molecular model and preclinical development of ACE2-selective radiopeptides
4. Prostate-Specific Membrane Antigen–Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes
5. Comparison of the dosimetry of scandium-43 and scandium-44 patient organ doses in relation to commonly used gallium-68 for imaging neuroendocrine tumours
6. Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer
7. Active bone marrow S-values for the low-energy electron emitter terbium-161 compared to S-values for lutetium-177 and yttrium-90
8. Combination of terbium-161 with somatostatin receptor antagonists—a potential paradigm shift for the treatment of neuroendocrine neoplasms
9. Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands
10. Promising potential of [177Lu]Lu-DOTA-folate to enhance tumor response to immunotherapy—a preclinical study using a syngeneic breast cancer model
11. Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates—new perspectives for folate receptor–targeted radionuclide therapy
12. Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC
13. Design and Preclinical Evaluation of a Novel Prostate-Specific Membrane Antigen Radioligand Modified with a Transthyretin Binder.
14. Theranostics -- a sure cure for cancer after 100 years?
15. Liquid Chromatography ICP-MS to Assess the Stability of 175 Lu- and nat Ga-Based Tumor-Targeting Agents towards the Development of 177 Lu- and 68 Ga-Labeled Radiopharmaceuticals.
16. First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum.
17. From Bench to Bedside—The Bad Berka Experience With First-in-Human Studies
18. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
19. Evaluation of the first 44Sc-labeled Affibody molecule for imaging of HER2-expressing tumors
20. O-31 - Introduction of terbium-161 into the clinics through its automated purification and the Good Manufacturing Practice compliant production of [161Tb]Tb-DOTA-LM3
21. Radiation dosimetry of 18F-AzaFol: A first in-human use of a folate receptor PET tracer
22. Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617
23. Albumin-Binding and Conventional PSMA Ligands in Combination with 161Tb: Biodistribution, Dosimetry, and Preclinical Therapy.
24. Investigations Using Albumin Binders to Modify the Tissue Distribution Profile of Radiopharmaceuticals Exemplified with Folate Radioconjugates.
25. 44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
26. 47Sc as useful β–-emitter for the radiotheragnostic paradigm: a comparative study of feasible production routes
27. Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy
28. Cyclotron production of 44Sc: From bench to bedside
29. Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer
30. Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy
31. Internal radiation dosimetry of a 152Tb-labeled antibody in tumor-bearing mice
32. 161Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of 161Tb into the Clinic.
33. Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of 161Tb-folate and 177Lu-folate
34. Preclinical in vivo application of 152Tb-DOTANOC: a radiolanthanide for PET imaging
35. [ 225 Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [ 225 Ac]Ac-PSMA-617.
36. 44Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations
37. Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics
38. Radiolabeling of rituximab with 188Re and 99mTc using the tricarbonyl technology
39. Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate
40. Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer.
41. Improved PET Imaging of Tumors in Mice Using a Novel 18 F-Folate Conjugate with an Albumin-Binding Entity
42. Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations
43. Preclinical Investigations to Explore the Difference between the Diastereomers [177Lu]Lu-SibuDAB and [177Lu]Lu-RibuDAB toward Prostate Cancer Therapy.
44. PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues
45. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues
46. Evaluation of a novel radiofolate in tumour-bearing mice: promising prospects for folate-based radionuclide therapy
47. Design and Evaluation of Novel Albumin-Binding Folate Radioconjugates: Systematic Approach of Varying the Linker Entities.
48. Expression of functional folate receptors by human parathyroid cells
49. Hsp90 Inhibition Protects Against Biomechanically Induced Osteoarthritis in Rats
50. In Vivo Labeling of Plasma Proteins for Imaging of Enhanced Vascular Permeability in the Lungs
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.